HLYK · Healthlynked Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $590.1K | $795.1K | $1.00M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $847.3K | - | $500.7K | $451.8K | $629.4K | - | $631.8K | $861.5K | $999.4K | - |
| Total Operating Expenses | $1.12M | - | $918.1K | $1.03M | $1.39M | - | $2.52M | $1.87M | $2.18M | - |
| D&A | $26.0K | - | $20.2K | $27.2K | $28.0K | - | $82.7K | $85.3K | $86.5K | - |
| Operating Income | ($700.8K) | - | ($529.6K) | ($435.4K) | ($617.4K) | - | ($1.67M) | ($1.08M) | ($1.18M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | $6.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.62M) | - | ($851.8K) | ($701.0K) | ($1.05M) | - | ($1.97M) | ($1.54M) | ($1.39M) | - |
| EPS - Basic | ($0.56) | - | ($0.30) | $0.00 | $0.00 | - | ($1.00) | ($1.00) | $0.00 | - |
| EPS - Diluted | ($0.56) | - | ($0.30) | $0.00 | $0.00 | - | ($1.00) | ($1.00) | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.0K | $37.1K | $10.9K | $20.2K | $22.3K | $76.2K | $15.0K | $172.7K | $23.5K | $247.2K |
| Accounts Receivable | - | - | - | - | - | - | $25.6K | $38.6K | $33.6K | $20.9K |
| Inventory | $18.5K | $18.0K | $32.0K | $27.6K | $32.3K | $44.7K | $78.8K | $96.4K | $136.2K | $133.2K |
| Accounts Payable | $648.9K | $530.7K | $580.3K | $575.1K | $543.8K | $468.8K | $470.7K | $527.6K | $372.6K | $251.5K |
| Current Assets | $1.54M | $1.55M | $1.54M | $1.56M | $1.57M | $1.64M | $1.82M | $2.01M | $1.90M | $656.2K |
| Total Assets | $1.63M | $1.70M | $1.76M | $1.85M | $2.06M | $2.22M | $2.76M | $3.86M | $3.89M | $4.28M |
| Current Liabilities | $8.20M | $7.01M | $6.74M | $6.13M | $5.60M | $4.69M | $3.81M | $3.40M | $2.69M | $2.41M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.65M | $7.46M | $7.20M | $6.60M | $6.19M | $5.35M | $4.69M | $4.28M | $3.67M | $3.48M |
| Stockholders' Equity | ($7.02M) | ($5.76M) | ($5.43M) | ($4.75M) | ($4.14M) | ($3.13M) | ($1.93M) | ($424.6K) | $221.5K | $804.7K |
| Retained Earnings | ($52.20M) | ($50.54M) | ($50.77M) | ($49.92M) | ($49.22M) | ($48.16M) | ($46.93M) | ($44.96M) | ($43.42M) | ($42.03M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($222.0K) | - | - | - | ($432.6K) | - | - | - | ($854.9K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($2.6K) | - |
| Financing Cash Flow | $208.8K | - | - | - | $378.6K | - | - | - | $633.7K | - |
| CapEx | - | - | - | - | - | - | - | - | $2.6K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($857.5K) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | -283.2% | -135.8% | -117.3% | - |
| EBITDA margin | - | - | - | - | - | - | -269.2% | -125.0% | -108.7% | - |
| Net margin | - | - | - | - | - | - | -334.4% | -193.7% | -138.2% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -85.4% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.62 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | 107.1% | 108.4% | 99.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -99.7% | - | -48.3% | -37.9% | -51.1% | - | -71.5% | -39.9% | -35.7% | - |
| Return on equity | 23.1% | - | 15.7% | 14.8% | 25.4% | - | 102.1% | 362.8% | -626.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.19 | 0.22 | 0.23 | 0.25 | 0.28 | 0.35 | 0.48 | 0.59 | 0.70 | 0.27 |
| Quick ratio | 0.19 | 0.22 | 0.22 | 0.25 | 0.27 | 0.34 | 0.46 | 0.56 | 0.65 | 0.22 |
| Cash ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.05 | 0.01 | 0.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -194.8x | - |
| Equity multiplier | -0.23 | -0.30 | -0.32 | -0.39 | -0.50 | -0.71 | -1.43 | -9.09 | 17.57 | 5.32 |
| Liabilities / Assets | 5.32 | 4.38 | 4.08 | 3.57 | 3.01 | 2.41 | 1.70 | 1.11 | 0.94 | 0.81 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.21 | 0.21 | 0.26 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | 16d | 18d | 12d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | 7218.1x | - |
| P / S | - | - | - | - | - | - | 2054.4x | 2693.6x | 1592.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | -55.7% | -53.3% | -42.8% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | -47.4% | -22.5% | -9.1% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -13.5% | - | 68.3% | 59.7% | 47.6% | - | -41.1% | -35.3% | -11.5% | - |
| Net income growth (YoY) | -54.3% | - | 56.8% | 54.5% | 24.3% | - | -1028.0% | -53.5% | - | - |
| EPS growth (YoY) | - | - | 70.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -69.7% | -84.1% | -181.1% | -1019.3% | - | - | - | - | -89.8% | 155.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$3.01M totalHealth Services$2.87M · 95.5%
Medical Distribution$103.8K · 3.4%
Digital Healthcare$32.4K · 1.1%
Product / service
$5.91M totalPatent Service Revenue Net$2.87M · 48.6%
Patient Service Revenue Net$2.87M · 48.6%
Product Revenue$103.8K · 1.8%
Subscription And Event Revenue$32.4K · 0.5%
Subscription Revenue$32.4K · 0.5%
Peer comparison
Same SIC group: Services-Offices & Clinics of Doctors of Medicine
Comparing HealthLynked Corp against the 5 most active filers in the same SIC group.